PULSE Session #18 Focuses on Sterile Drug Manufacturing Compliance Under Revised Schedule M

A recent PULSE initiative session addressed critical aspects of sterile drug product manufacturing. The session, the 18th in the PULSE series, concentrated on regulatory compliance, operational standards, and ensuring technical readiness within the pharmaceutical sector. Specifically, FOPE and PharmaState Academy jointly conducted the session, focusing on sterile drug manufacturing practices as outlined in the Revised Schedule M. The session provided detailed information on how manufacturers can adhere to updated regulatory guidelines and maintain high operational standards, ultimately contributing to the safe and effective production of sterile drugs. Technical preparedness ensures manufacturers can adopt advanced technologies and methodologies.

Newsflash | Powered by GeneOnline AI
Date: April 9, 2025

Related posts:

Drug Patent Searching: Essential Process as New Drug Development Increases Annually FTO Analysis Impacts Stability Testing for Generic Drug Manufacturers Seeking Market Entry Study Finds 1,000-Person Survey Reveals Cost Still Outweighs Sustainability for Many Consumers Explicit Instruction Boosts Reading Comprehension Scores in Elementary Students, Study Finds

Author

Mark Chiang